Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial

Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours

(2014) Constance Thibault et al.   EUROPEAN JOURNAL OF CANCER

Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors

(2012) C. Massard et al.   ANNALS OF ONCOLOGY

Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer

(2012) J. Beyer et al.   ANNALS OF ONCOLOGY

Sequential Versus Single High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: Long-Term Results of a Prospective Randomized Trial

(2012) Anja Lorch et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Study Comparing Paclitaxel–Bleomycin, Etoposide, and Cisplatin (BEP) to Standard BEP in Intermediate-Prognosis Germ-Cell Cancer: Intergroup Study EORTC 30983

(2012) Ronald de Wit et al.   JOURNAL OF CLINICAL ONCOLOGY

EAU Guidelines on Testicular Cancer: 2011 Update

(2011) Peter Albers et al.   EUROPEAN UROLOGY

Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database

(2011) Anja Lorch et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy

(2010)   JOURNAL OF CLINICAL ONCOLOGY